



Policy Title :		
Hepatitis B Immunization		
Department	Index No.	Scope
INFECTION CONTROL	ICD-010	Hospital wide
Issue Date	Revision NO	Effective Date
08/15/1432	4	15/11/2020
Review Due Date	Related Standard NO.	Page Number#
20/11/2022	CBAHI (IPC 36)	Page 1 of 3

01. Policy:

- 01.1. All healthcare workers of AQGH at risk of exposure to blood or body fluids should ensure that they are adequately immunized against Hepatitis B virus
- 01.2. All new HCWs will be tested for Hepatitis B immunity unless a reliable document on immunity status can be provided.
- 01.3. All Hepatitis vaccinations and screenings should be documented

02. Definition :

- 02.1. HCW- Health Care Worker
- 02.2. HBsAg- Hepatitis B surface antigen
- 02.3. (anti- HBS) Hepatitis B surface antibody

03. Purpose :

- 03.1. To provide guidelines on Hepatitis B immunization.

04. Procedure :

04.1. Pre-vaccination Testing

- 04.1.1. Screen all new HCWs for HBsAg and anti-HBs to verify HBV immune status.
- 04.1.2. Provide Hepatitis B immunization to those HCWs who are non-immune for Hepatitis B, i.e those with anti-HBs < 10 mIU/L, unless they provide documentation of a completed vaccination series and anti-HBs levels > 10 mIU/L 1 to 2 months post-vaccination.
- 04.1.3. Explain the risks of non-immunization to all HCWs who refuse immunization and have them sign a disclaimer form if they refuse immunization.



وزارة الصحة

Ministry of Health

مستشفى القنفذة العام

04.2. Administration of the Vaccine

- 04.2.1. Give three doses of Hepatitis B vaccine with the second and third doses at 1 and 6 month intervals, as recommended by the manufacturer (as per package insert).
- 04.2.2. Use a 22 to 25 gauge needle, at least 1 to 1.5 inches long. Administer 1.0 ml intramuscularly (IM) into the deltoid muscle. Do not administer in the gluteal region; if this has been done, the dose should be repeated.

04.3. Post-vaccination Serological Testing

- 04.3.1. To ensure adequate seroconversion and protection:
 - One to two months after completing the series, the vaccine level of anti-HBs is expected to be > 10 mIU/L, and this value should be checked in any HCW with patient exposure.

04.4. Non-responders to the First Series of Vaccination

If anti-HBs levels are < 10 mIU/L 1 to 2 months post-vaccination, take the following steps:

- 04.4.1. A full second series of 3 doses should be given.
- 04.4.2. One month after completing the second series, the vaccine level of anti-HBs is expected to be > 10 mIU/L, and this value should be checked in any HCW with patient exposure
- 04.4.3. If the HCW remains anti-HBs-negative, then he/she is considered a non-responder and should be counseled accordingly.

04.5. Counseling Non-responders


- 04.5.1. If all of the above measures were taken and the HCW remains anti-HBs-negative, no further doses should be given.
- 04.5.2. The importance of standard precautions and policy should be stressed to the HCW.
- 04.5.3. The HCW should receive an HBsAg test; if positive, he/she should receive counseling as mentioned above. Professional duties should be reviewed along with appropriate referrals.
- 04.5.4. HBsAg-negative HCWs who fail to seroconvert should receive HBIG if exposed to HBsAg positive blood products or body fluid.

05. Responsibilities :

- 05.1. Employee Health Clinic, Infection Control, Laboratory, pharmacy, Head of Departments

06. Equipment & Forms

- 06.1. Hepatitis B Vaccine
- 06.2. Syringe with 22-25 gauge needle. One to one and a half inch long
- 06.3. Alcohol swabs
- 06.4. Vaccination record and vaccination card



وزارة الصحة

Ministry of Health

مستشفى القفزة العام

07. Attachment :

07.1. N/A

08. Reference

08.1. GCC Infection Prevention and Control Manual 3rd edition 2018

Preparation, Reviewing & Approval Box

	NAME	Position	Signature	Date
Prepared By	DR. FOUED ROMDHANE	Infection Control Coordinator		15/11/2020
Reviewed By	MR. AHMED IBRAHIM BALBID	Infection Control Director		15/11/2020
Reviewed By	MS. AMRAH HADI ALHILEESI	Nursing Director		16-11-2020
Reviewed By	MS. RAHMA ALSANAA	TQM Director		15.11.2020
Reviewed By	DR. AMAL SHAMI AL HASSANI	Medical Director		15.11.2020
Approved By	MR. HUSSAIN ALY AL MONTASHRY	Hospital Director and Chairman of ICC		13/11/20

